Evidence map›Paper›PMID 41288687›Full record

ArticleSocial psychiatry and psychiatric epidemiology2026

Clinical outcomes in first-episode schizophrenia: identifying predictors of relapse.

Mulualem Kelebie, Getasew Kibralew, Setegn Fentahun, Gidey Rtbey, Mekidem Aderaw, Wondale Endeshaw, Mitiku Belachew, Mulu Muche, Girum Nakie, Kindye Tesfaw and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Social psychiatry and psychiatric epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mulualem KelebieDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia. mulualem2323@gmail.com.
Getasew KibralewDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Setegn FentahunDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Gidey RtbeyDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Mekidem AderawDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Wondale EndeshawDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Mitiku BelachewDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Mulu MucheDepartment of Environmental Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia.
Girum NakieDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Kindye TesfawDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, Bahirdar University, Bahirdar, Ethiopia.
Girmaw Medfu TakelleDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Gebresilassie TadesseDepartment of Psychiatry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSchizophrenia is a chronic psychiatric disorder marked by recurrent relapses, which significantly affect long-term clinical and functional outcomes. Early relapse following a first episode of psychosis is linked to increased illness chronicity, higher hospitalization rates, and greater psychosocial impairment. While antipsychotic treatment can reduce the risk of relapse, recurrence remains common. Identifying predictors of relapse is essential for optimizing treatment strategies; however, evidence from low-resource settings, such as Ethiopia, is limited. This study aimed to examine clinical outcomes and identify key predictors of relapse among individuals with first-episode schizophrenia in Ethiopia.

methodsAn institutional-based retrospective cohort study was conducted at the University of Gondar Specialized Hospital, including 710 adults diagnosed with schizophrenia who received antipsychotic treatment and maintained regular follow-up over one year. Clinical outcomes were assessed using the Clinical Global Impressions-Schizophrenia (CGI-SCH) scale, which evaluates symptom severity across positive, negative, depressive, and cognitive domains and Outcomes were dichotomized into good clinical improvement and poor clinical improvement. Antipsychotic side effects and medication adherence were assessed using the Glasgow Antipsychotic Side-Effects Scale (GASS) and the Medication Adherence Rating Scale (MARS-10), respectively. Clinical outcomes and predictors of relapse were analyzed using Cox proportional hazards and multivariable logistic regression models, with statistical significance set at P < 0.05.

resultsAmong the 710 individuals diagnosed with schizophrenia, 457 (64.4%) achieved favorable clinical outcomes. The highest therapeutic response was observed in patients treated with Olanzapine, with 168 (36.8%) demonstrating significant clinical improvement. During the follow-up period, 33.5% of patients experienced at least one relapse episode. In multivariable Cox regression analysis, younger age (18-30 years; AHR = 1.43, 95% CI: 1.07-1.9), living alone (AHR = 1.31, 95% CI: 1.03-1.73), a positive family history of suicidal attempts (AHR = 1.45, 95% CI: 1.13-1.85), and the presence of moderate anti-psychotic side effects (AHR = 2.23, 95% CI: 1.42-3.5) were significant predictors of poor clinical outcomes. Furthermore, poor medication adherence (OR = 1.57, 95% CI: 1.07-2.13), presence of suicidal ideation (OR = 2.22, 95% CI: 1.54-3.22), younger age (OR = 1.42, 95% CI: 1.11-1.81), and lack of formal education (OR = 1.30, 95% CI: 1.10-1.53) were significant predictors of relapse among individuals with schizophrenia.

conclusionThis study reveals that most individuals with schizophrenia achieve favorable clinical outcomes, relapse remains a major concern, affecting about one-third of patients. Poor outcomes are significantly associated with younger age, living alone, a family history of suicidal attempts, and moderate anti-psychotic side effects, whereas relapse is more likely among those with poor medication adherence, suicidal ideation, younger age, and lack of formal education. These findings highlight the need for early identification of high-risk patients and the implementation of targeted interventions to improve adherence, reduce relapse, and enhance recovery, especially in resource-limited settings.

Indexed as

Antipsychotic AgentsSchizophreniaSchizophrenic PsychologyAdolescentAdultEthiopiaFemaleHumansMaleMedication AdherenceMiddle AgedPsychiatric Status Rating ScalesRecurrenceRetrospective StudiesTreatment OutcomeYoung AdultAntipsychotic AgentsOutcomePredictorsRelapseSchizophrenia and ethiopia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.